Literature DB >> 32968199

Thrombin-Par1 signaling axis disrupts COP9 signalosome subunit 3-mediated ABCA1 stabilization in inducing foam cell formation and atherogenesis.

Monoranjan Boro1, Suresh Govatati1, Raj Kumar1, Nikhlesh K Singh1, Prahalathan Pichavaram1, James G Traylor2, A Wayne Orr2, Gadiparthi N Rao3.   

Abstract

ATP-binding cassette transporters A1 (ABCA1) and G1 (ABCG1) play a vital role in promoting cholesterol efflux. Although, the dysregulation of these transporters was attributed as one of the mechanisms of atherogenesis, what renders their dysfunction is not well explored. Previously, we have reported that thrombin without having any effect on ABCG1 levels depletes ABCA1 levels affecting cholesterol efflux. In this study, we explored the mechanisms underlying thrombin-induced depletion of ABCA1 levels both in macrophages and smooth muscle cells. Under normal physiological conditions, COP9 signalosome subunit 3 (CSN3) was found to exist in complex with ABCA1 and in the presence of proatherogenic stimulants such as thrombin, ABCA1 was phosphorylated and dissociated from CSN3, leading to its degradation. Forced expression of CSN3 inhibited thrombin-induced ABCA1 ubiquitination and degradation, restored cholesterol efflux and suppressed foam cell formation. In Western diet (WD)-fed ApoE-/- mice, CSN3 was also disassociated from ABCA1 otherwise remained as a complex in Chow diet (CD)-fed ApoE-/- mice. Interestingly, depletion of CSN3 levels in WD-fed ApoE-/- mice significantly lowered ABCA1 levels, inhibited cholesterol efflux and intensified foam cell formation exacerbating the lipid laden atherosclerotic plaque formation. Mechanistic studies have revealed the involvement of Par1-Gα12-Pyk2-Gab1-PKCθ signaling in triggering phosphorylation of ABCA1 and its disassociation from CSN3 curtailing cholesterol efflux and amplifying foam cell formation. In addition, although both CSN3 and ABCA1 were found to be colocalized in human non-lesion coronary arteries, their levels were decreased as well as dissociated from each other in advanced atherosclerotic lesions. Together, these observations reveal for the first time an anti-atherogenic role of CSN3 and hence, designing therapeutic drugs protecting its interactions with ABCA1 could be beneficial against atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32968199      PMCID: PMC7862243          DOI: 10.1038/s41418-020-00623-9

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  2 in total

Review 1.  The COP9 signalosome: at the interface between signal transduction and ubiquitin-dependent proteolysis.

Authors:  Dawadschargal Bech-Otschir; Michael Seeger; Wolfgang Dubiel
Journal:  J Cell Sci       Date:  2002-02-01       Impact factor: 5.285

2.  Activation of NLRP3 Inflammasome Promotes Foam Cell Formation in Vascular Smooth Muscle Cells and Atherogenesis Via HMGB1.

Authors:  Rui Wang; Weibin Wu; Wen Li; Shuichuan Huang; Zilun Li; Ruiming Liu; Zhen Shan; Chunxiang Zhang; Wen Li; Shenming Wang
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

  2 in total
  4 in total

Review 1.  Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis.

Authors:  Li-Ping Jiang; Xiao-Hua Yu; Jin-Zhi Chen; Mi Hu; Yang-Kai Zhang; Hui-Ling Lin; Wan-Ying Tang; Ping-Ping He; Xin-Ping Ouyang
Journal:  Aging Dis       Date:  2022-06-01       Impact factor: 9.968

2.  COP9 Signalosome Subunit 3 Restricts Neuroinflammatory Responses During Cerebral Ischemia/Reperfusion Injury Through Stabilizing Suppressor of Cytokine Signaling 3 Protein.

Authors:  En Liang; Xiaojun Li; Wenjun Fu; Changtong Zhao; Baoying Yang; Zhonghua Yang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-04-22       Impact factor: 2.570

Review 3.  Role of ABCA1 in Cardiovascular Disease.

Authors:  Jing Wang; Qianqian Xiao; Luyun Wang; Yan Wang; Daowen Wang; Hu Ding
Journal:  J Pers Med       Date:  2022-06-20

4.  Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation.

Authors:  Julian Friebel; Eileen Moritz; Marco Witkowski; Kai Jakobs; Elisabeth Strässler; Andrea Dörner; Daniel Steffens; Marianna Puccini; Stella Lammel; Rainer Glauben; Franziska Nowak; Nicolle Kränkel; Arash Haghikia; Verena Moos; Heinz-Peter Schutheiss; Stephan B Felix; Ulf Landmesser; Bernhard H Rauch; Ursula Rauch
Journal:  Cells       Date:  2021-12-13       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.